Polaris Group
Clinical trials sponsored by Polaris Group, explained in plain language.
-
New drug shows promise for fatty liver in early trial
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive either the drug or a placebo to see if it safely reduces liver fat over 24 weeks. The goal is to find a new treatment that controls…
Phase: PHASE2 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for rare cancer: drug combo targets tumor growth
Disease control Recruiting nowThis phase 3 trial tests whether adding ADI-PEG 20 to standard chemotherapy (gemcitabine and docetaxel) helps control advanced leiomyosarcoma, a rare soft tissue cancer. About 300 adults whose cancer has worsened after prior treatment will receive either the study drug or a place…
Phase: PHASE3 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New drug targets arginine to fight liver cancer in phase 3 trial
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery and who have high levels of the amino acid arginine in their blood. The goal is to see if the drug helps people live longer. Participants must ha…
Phase: PHASE3 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 11, 2026 20:38 UTC